Brokers are bullish about these 3 ASX 200 shares

Brokers see upside in ASX 200 shares including Eagers Automotive Ltd (ASX: APE) and AGL Energy Limited (ASX: AGL)

| More on:
Woman in pink shirt ticks checklist with red checkmarks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These 3 ASX 200 shares have struggled to deliver shareholder value in the past few months. Big brokers have scrutinised them and believe there could be some upside as earnings momentum recovers or picks up.  

1. AGL Energy Limited (ASX: AGL

Ord Minnett thinks that the tides may have finally turned for the depressed AGL share price. The broker believes that there could be some significant asset restructuring from the company in the near-term, but expects the focus will be to improve the profitability of its assets.

Ord Minnett rates the AGL share price as an 'accumulate' with a $14.04 share price target. This would represent a significant ~40% upside to its current levels. 

2. Eagers Automotive Ltd (ASX: APE

In June 2020, Mercedes-Benz and Honda announced a move from a franchise-based dealership model to a new business model that uses dealers as intermediaries to sell cars from the manufacturer. 

Honda is expected to start the new business model in July 2021, while Mercedes-Benz hopes to transition by January 2022. 

Morgan Stanley believes that this transition will not impact Eagers Automotive's profitability and that the agency model itself would not be widely adopted any time soon. It also notes that Eagers Automotive has relatively low exposure to the two brands. 

The broker retained an overweight rating for Eagers Automotive, with a $17.00 target price. 

3. Sonic Healthcare Limited (ASX: SHL)

The Australian government announced an additional $1.1 billion in funding for Australia's health response to COVID-19 this month. This investment will support rapid pathology testing and tracing, building on the more than 14.5 million COVID tests conducted to date. 

Sonic has played a crucial role in pandemic control with over 18 million COVID tests performed to date in 60 Sonic laboratories globally. COVID-19 testing has emerged as a significant revenue and earnings contributor alongside its core medical diagnostic services. The additional funding from the Australian government means that the current $100 COVID-19 test fee will remain in place. Credit Suisse expected this fee would be reduced to $50 from 1 April. 

The broker believes that the company should see a recovery in growth rates moving into the second half of FY21. Sonic has noted that its global business has become increasingly resilient to the impacts of pandemic waves, evidenced by only a 1% decline in revenue during 1H FY21. 

Credit Suisse rates Sonic as an outperform with a $40.00 target price. 

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a wild ride this Thursday.

Read more »

Two men in hard hats and high visibility jackets look together at a laptop screen at a mine site.
Gold

Down 50% in a year, time to pounce on this beaten-down ASX 200 gold stock?

A leading expert offers his verdict on this beaten-down ASX 200 gold miner.

Read more »

A view of competitors in a running event, some wearing number bibs, line up together on a starting line looking ahead as if to start a race.
Best Shares

Best ASX 200 share of each market sector in FY25

Did you own any of these ASX 200 winners in FY25?

Read more »

children and teacher in childcare education setting
Broker Notes

Why did Macquarie just re-rate G8 Education shares?

G8 Education shares are down 23% this year.

Read more »

IPO written in yellow and stuck in the air.
IPOs

End of the IPO drought: GemLife listing one of the biggest of the year

The GemLife IPO is the third major ASX listing in less than a month.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Share Market News

Why brokers says these ASX dividend stocks are top buys for income investors

Want an income boost? Take a look at these stocks that brokers rate as buys.

Read more »

A man looking at his laptop and thinking.
Broker Notes

After crashing more than 21% yesterday, does Macquarie rate Helia shares a buy?

Should I buy the big dip on Helia shares? Here’s Macquarie’s latest share price forecast.

Read more »

Happy work colleagues give each other a fist pump.
Broker Notes

Buy this ASX 200 share that is having a 'milestone year'

Bell Potter has good things to say about this high-flying stock.

Read more »